Skip to main content
Fig. 4 | Stem Cell Research & Therapy

Fig. 4

From: Galectin-9 is required for endometrial regenerative cells to induce long-term cardiac allograft survival in mice

Fig. 4

Gal-9-ERC-based therapy alleviated pathological manifestation and prolonged allograft survival time. A Heterotopic cardiac transplantations (BALB/c to B6, n = 6) were performed, and a different immunotherapy was administrated successively. The mean survival time (MST) among different groups was compared, and survival analysis was conducted through the Kaplan-Meier cumulative survival method. B After receiving treatments, human-derived Gal-9 mRNA expression were evaluated in the murine cardiac allografts (n = 6). C Histology of cardiac allografts from B6 recipients on POD8. Representative sections among each group was harvested and stained for H&E staining (× 200 magnification). D–I To evaluate CD4+ T cell deviations and pro-cytokine expressions in allografts, relative mRNA expression of T-bet (D), RORyt (E), Foxp3 (F), IFN-γ (G), IL-17 (H), and EBI-3 (I) were separately analyzed, indicating Th1, Th17, and Treg deviations in grafts (n = 6). Differences among groups were assessed by using one-way analysis of variance (ANOVA). *p < 0.05, **p < 0.01. Abbreviations: ERC, endometrial regenerative cell; Gal-9-ERC, Galectin-9 high-expression ERC; POD, postoperative day; Rapa, rapamycin

Back to article page